Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


01.01.2018

2 AIDS
2 Am J Gastroenterol
1 Ann Intern Med
1 Arch Virol
2 BMC Gastroenterol
2 Clin Infect Dis
2 Eur J Gastroenterol Hepatol
1 Gastroenterol Hepatol
3 Gastroenterology
1 Hepatology
2 J Hepatol
1 J Immunol
1 J Med Virol
1 J Pediatr
8 J Viral Hepat
5 PLoS One
2 PLoS Pathog
1 Proc Natl Acad Sci U S A
1 Transplantation
1 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AIDS

  1. YOUNAS M, Carrat F, Finge S, Desaint C, et al
    Immune activation, smoking, and vaccine response.
    AIDS. 2016.
    PubMed     Text format     Abstract available

  2. AUDSLEY J, Bent SJ, Littlejohn M, Avihingsanon A, et al
    Effects of long-term tenofovir-based cART in HIV-HBV co-infection on persistent HBV viremia and the role of HBV quasispecies diversity.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    Am J Gastroenterol

  3. NGUYEN MH, Trinh H, Do S, Nguyen T, et al
    Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naive or Experienced Patients.
    Am J Gastroenterol. 2017;112:1824-1831.
    PubMed     Text format     Abstract available

  4. HUANG YW, Lee CL, Yang SS, Fu SC, et al
    Corrigendum: Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.
    Am J Gastroenterol. 2017 Dec 26. pii: ajg2017494. doi: 10.1038/ajg.2017.
    PubMed     Text format     Abstract available


    Ann Intern Med

  5. WEISER J, Perez A, Bradley H, King H, et al
    Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012.
    Ann Intern Med. 2017 Dec 26. pii: 2667091. doi: 10.7326/M17-1689.
    PubMed     Text format     Abstract available


    Arch Virol

  6. ISHIBASHI M, Yamaguchi H, Hirotani Y, Sakurada A, et al
    Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers.
    Arch Virol. 2017 Dec 16. pii: 10.1007/s00705-017-3675.
    PubMed     Text format     Abstract available


    BMC Gastroenterol

  7. LEI JW, Ji XY, Hong JF, Li WB, et al
    Prediction of posthepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma.
    BMC Gastroenterol. 2017;17:171.
    PubMed     Text format     Abstract available

  8. ALONSO S, Guerra AR, Carreira L, Ferrer JA, et al
    Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    BMC Gastroenterol. 2017;17:168.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  9. HUA S, Vigano S, Tse S, Zhengyu O, et al
    Pegylated IFN-alpha-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients.
    Clin Infect Dis. 2017 Dec 20. pii: 4767848. doi: 10.1093/cid/cix1111.
    PubMed     Text format     Abstract available

  10. YOUNOSSI ZM, Stepanova M, Asselah T, Foster G, et al
    Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.
    Clin Infect Dis. 2017 Dec 20. pii: 4766885. doi: 10.1093/cid/cix1106.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  11. HUANG R, Zhao XA, Wang J, Hao Y, et al
    Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:241.
    PubMed     Text format    

  12. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Text format     Abstract available


    Gastroenterol Hepatol

  13. GUARDIOLA-AREVALO A, Gomez Rodriguez R, Romero Gutierrez M, Gomez Moreno AZ, et al
    Hepatitis B virus e antigen-negative chronic infection. Treatment based on glutamic pyruvic transaminase and hepatitis B virus deoxyribonucleic acid cut-off values.
    Gastroenterol Hepatol. 2017 Dec 23. pii: S0210-5705(17)30243.
    PubMed     Text format     Abstract available


    Gastroenterology

  14. POURCET B, Zecchin M, Ferri L, Beauchamp J, et al
    Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity Of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice.
    Gastroenterology. 2017 Dec 22. pii: S0016-5085(17)36725.
    PubMed     Text format     Abstract available

  15. WU X, Dao Thi VL, Liu P, Takacs CN, et al
    Pan-Genotype Hepatitis E Virus Replication in Stem Cell-derived Hepatocellular Systems.
    Gastroenterology. 2017 Dec 22. pii: S0016-5085(17)36303.
    PubMed     Text format     Abstract available

  16. GOTTWEIN JM, Pham LV, Mikkelsen LS, Ghanem L, et al
    Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gastroenterology. 2017 Dec 21. pii: S0016-5085(17)36720.
    PubMed     Text format     Abstract available


    Hepatology

  17. GRAKOUI A, Walker CM
    Of mice, rats and men: Small animal model of hepatitis C virus infection.
    Hepatology. 2017 Dec 27. doi: 10.1002/hep.29765.
    PubMed     Text format    


    J Hepatol

  18. BORST K, Frenz T, Spanier J, Tegtmeyer PK, et al
    Type I interferon receptor-signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis.
    J Hepatol. 2017 Dec 2. pii: S0168-8278(17)32473.
    PubMed     Text format     Abstract available

  19. SCOTT N, Olafsson S, Gottfreethsson M, Tyrfingsson T, et al
    Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
    J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32528.
    PubMed     Text format     Abstract available


    J Immunol

  20. MENDEZ-LAGARES G, Lu D, Chen C, Terrault N, et al
    Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.
    J Immunol. 2017 Dec 20. pii: jimmunol.1701364. doi: 10.4049/jimmunol.1701364.
    PubMed     Text format     Abstract available


    J Med Virol

  21. ZHU MY, Chen PZ, Li J, Yu DM, et al
    Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-alpha treatment in HBeAg-positive chronic hepatitis B patients.
    J Med Virol. 2017 Dec 16. doi: 10.1002/jmv.25010.
    PubMed     Text format     Abstract available


    J Pediatr

  22. RICCIUTO A, Kamath BM, Walters TD, Frost K, et al
    New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children.
    J Pediatr. 2017 Dec 21. pii: S0022-3476(17)31491.
    PubMed     Text format     Abstract available


    J Viral Hepat

  23. ZENG QL, Xu GH, Wang B, Li ZQ, et al
    Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12848.
    PubMed     Text format     Abstract available

  24. GUBAY F, Staunton R, Metzig C, Abubakar I, et al
    Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
    PubMed     Text format     Abstract available

  25. MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
    Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
    PubMed     Text format     Abstract available

  26. KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
    The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
    PubMed     Text format     Abstract available

  27. CHEN CH, Hsu YC, Lu SN, Hung CH, et al
    The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12851.
    PubMed     Text format     Abstract available

  28. HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
    Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
    PubMed     Text format     Abstract available

  29. SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
    Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
    PubMed     Text format     Abstract available

  30. EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
    Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
    PubMed     Text format     Abstract available


    PLoS One

  31. LAY P, An S, Soeung S, Srey PS, et al
    Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes.
    PLoS One. 2017;12:e0185348.
    PubMed     Text format     Abstract available

  32. BROQUETAS T, Garcia-Retortillo M, Hernandez JJ, Puigvehi M, et al
    Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.
    PLoS One. 2017;12:e0188303.
    PubMed     Text format     Abstract available

  33. DERESSA T, Damtie D, Fonseca K, Gao S, et al
    The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia.
    PLoS One. 2017;12:e0190149.
    PubMed     Text format     Abstract available

  34. PANNETIER J, Gigonzac V, Lydie N, Desgrees du Lou A, et al
    Timing of chronic hepatitis B diagnosis after migration and its determinants among Sub-Saharan African migrants living in France.
    PLoS One. 2017;12:e0189196.
    PubMed     Text format     Abstract available

  35. YIN F, Xie Y, Fan H, Zhang J, et al
    Mutations in hepatitis B virus polymerase are associated with the postoperative survival of hepatocellular carcinoma patients.
    PLoS One. 2017;12:e0189730.
    PubMed     Text format     Abstract available


    PLoS Pathog

  36. DENOLLY S, Mialon C, Bourlet T, Amirache F, et al
    The amino-terminus of the hepatitis C virus (HCV) p7 viroporin and its cleavage from glycoprotein E2-p7 precursor determine specific infectivity and secretion levels of HCV particle types.
    PLoS Pathog. 2017;13:e1006774.
    PubMed     Text format     Abstract available

  37. GOPAL R, Jackson K, Tzarum N, Kong L, et al
    Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.
    PLoS Pathog. 2017;13:e1006735.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  38. MANKOWSKI MC, Kinchen VJ, Wasilewski LN, Flyak AI, et al
    Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.
    Proc Natl Acad Sci U S A. 2017 Dec 18. pii: 1718441115.
    PubMed     Text format     Abstract available


    Transplantation

  39. GARCIA CR, Acosta LF, Mei X, Berger J, et al
    Liver Transplantation for the Treatment of Complicated Iatrogenic Biliary Injuries: A National Review from the UNOS Dataset.
    Transplantation. 2017 Aug 22. doi: 10.1097/TP.0000000000001922.
    PubMed     Text format     Abstract available


    Vaccine

  40. SHIVE CL, Judge CJ, Clagett B, Kalayjian RC, et al
    Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.
    Vaccine. 2017 Dec 15. pii: S0264-410X(17)31761.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: